https://www.biopharmawatch.com/news/GENB/generate-biomedicines-september-investor-conferences BiopharmaWatch en 2026-09-08T11:09:00.000Z Generate Biomedicines Inc. to Participate in September Investor Conferences https://www.biopharmawatch.com/news/HLF/herbalife-250-million-share-repurchase-program BiopharmaWatch en 2026-09-08T11:05:00.000Z Herbalife Announces $250 Million Share Repurchase Program https://www.biopharmawatch.com/news/ZBIO/zenas-biopharma-obexelimab-ig4-rd-event BiopharmaWatch en 2026-09-08T11:05:00.000Z Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event https://www.biopharmawatch.com/news/IVVD/invivyd-participate-september-investor-conferences BiopharmaWatch en 2026-09-08T11:01:00.000Z Invivyd to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/UTHR/united-therapeutics-accelerated-share-repurchase-agreement BiopharmaWatch en 2026-09-08T11:00:00.000Z United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-breakthrough-therapy-dt120-mdd BiopharmaWatch en 2026-09-08T11:00:00.000Z Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results https://www.biopharmawatch.com/news/CGEN/compugen-fireside-chat-hc-wainwright-conference BiopharmaWatch en 2026-09-08T11:00:00.000Z Compugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/PLSM/pulsenmore-expands-fertility-care-home-ultrasound-system BiopharmaWatch en 2026-09-08T11:00:00.000Z Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring https://www.biopharmawatch.com/news/KURA/kura-oncology-appoints-jennifer-fulk-cfo BiopharmaWatch en 2026-09-08T11:00:00.000Z Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer https://www.biopharmawatch.com/news/ANL/adlai-nortye-first-patient-dosed-an4035-trial BiopharmaWatch en 2026-09-08T11:00:00.000Z Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC https://www.biopharmawatch.com/news/TNXP/tonix-pharmaceuticals-promotes-thomas-englese-cc BiopharmaWatch en 2026-09-08T11:00:00.000Z Tonix Pharmaceuticals Promotes Thomas Englese, MBA, to Chief Commercial Officer https://www.biopharmawatch.com/news/GLUE/monte-rosa-phase-2-study-sjogrens-disease BiopharmaWatch en 2026-09-08T11:00:00.000Z Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) https://www.biopharmawatch.com/news/CALC/calcimedica-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z CalciMedica to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ERAS/erasca-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/AVIR/atea-pharmaceuticals-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/TLRY/brewdog-leicester-tigers-partnership-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z BrewDog Roars into Rugby with Five-Year Leicester Tigers Partnership, Bringing Punk Energy to Welford Road https://www.biopharmawatch.com/news/OKYO/okyo-pharma-cantor-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/NKTX/nkarta-present-initial-autoimmune-clinical-data-acr-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 https://www.biopharmawatch.com/news/NRXP/nrx-pharmaceuticals-investor-conferences-september-2026 BiopharmaWatch en 2026-09-08T11:00:00.000Z NRx Pharmaceuticals to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/EDIT/editas-medicine-appoints-dan-ory-cmo BiopharmaWatch en 2026-09-08T11:00:00.000Z Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer https://www.biopharmawatch.com/news/NBP/novabridge-appoints-martin-dewhurst-board-directors BiopharmaWatch en 2026-09-08T11:00:00.000Z NovaBridge Appoints Martin Dewhurst to Board of Directors as an Independent Director https://www.biopharmawatch.com/news/BMY/bms-quintessential-trial-results-arlocabtagene BiopharmaWatch en 2026-09-08T10:59:00.000Z Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... https://www.biopharmawatch.com/news/PHVS/pharvaris-chapter-3-study-positive-results BiopharmaWatch en 2026-09-08T10:50:00.000Z Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks https://www.biopharmawatch.com/news/MRK/merck-participate-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-08T10:45:00.000Z Merck to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/PLX/protalix-biotherapeutics-september-2026-investor-conferences BiopharmaWatch en 2026-09-08T10:45:00.000Z Protalix BioTherapeutics to Participate in Upcoming September 2026 Investor Conferences https://www.biopharmawatch.com/news/TFX/teleflex-appoints-sean-salmon-board-directors BiopharmaWatch en 2026-09-08T10:30:00.000Z Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors https://www.biopharmawatch.com/news/HSIC/henry-schein-investor-conference-september-2026 BiopharmaWatch en 2026-09-08T10:30:00.000Z Henry Schein to Participate in Upcoming Investor Conference in September https://www.biopharmawatch.com/news/CMPS/compass-pathways-hcp-education-campaign-psych-congress-2026 BiopharmaWatch en 2026-09-08T10:30:00.000Z Compass Pathways to Debut U.S. HCP Education Campaign and Present New HEOR Data at Psych Congress 2026 https://www.biopharmawatch.com/news/CAI/caris-life-sciences-launches-national-campaign-early-cancer-detection BiopharmaWatch en 2026-09-08T10:30:00.000Z Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect https://www.biopharmawatch.com/news/BJDX/bluejay-diagnostics-lovell-partnership-federal-healthcare BiopharmaWatch en 2026-09-08T10:30:00.000Z Bluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare Markets https://www.biopharmawatch.com/news/RDNT/radnet-presentation-jefferies-conference-september-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z RadNet, Inc. to Present at the Jefferies Healthcare Services and Technology Conference on September 15, 2026 https://www.biopharmawatch.com/news/MNOV/medicinova-investor-conferences-september-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z MediciNova to Participate in Two Investor Conferences in September https://www.biopharmawatch.com/news/GMAB/extraordinary-general-meeting-genmab-october-2026 BiopharmaWatch en 2026-09-08T10:00:00.000Z Notice to Convene an Extraordinary General Meeting of Genmab A/S https://www.biopharmawatch.com/news/ROIV/pulmovant-positive-results-phocus-study-mosliciguat BiopharmaWatch en 2026-09-08T10:00:00.000Z Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study https://www.biopharmawatch.com/news/BLTE/belite-bio-submission-new-drug-application-japan BiopharmaWatch en 2026-09-08T10:00:00.000Z Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1 https://www.biopharmawatch.com/news/UPB/upstream-bio-phase-2-valiant-trial-verekitug-asthma BiopharmaWatch en 2026-09-08T07:30:00.000Z Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026 https://www.biopharmawatch.com/news/DTC/defence-therapeutics-ceo-shareholder-letter BiopharmaWatch en 2026-09-08T07:15:00.000Z Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders https://www.biopharmawatch.com/news/MEDS/datameds-ai-tollo-health-nfl-alumni-partnership BiopharmaWatch en 2026-09-08T06:00:00.000Z Datameds, AI., and Tollo Health Partner with the NFL Alumni Association for Health Lives Here National Campaign Rollout https://www.biopharmawatch.com/news/NVS/novartis-delpacibart-etedesiran-phase-iii-harbor-study-update BiopharmaWatch en 2026-09-08T05:00:00.000Z Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1) https://www.biopharmawatch.com/news/BNXT/bionxt-sublingual-everolimus-odf-study BiopharmaWatch en 2026-09-08T03:05:00.000Z BioNxt Advances Sublingual Everolimus ODF for Organ Transplant Rejection with Initiation of Large-Animal Pharmacokinetic Study https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-slabs-trial-success BiopharmaWatch en 2026-09-08T02:00:00.000Z Genflow Biosciences PLC Announces Primary Endpoint in SLAB Clinical Trial Met https://www.biopharmawatch.com/news/NYXH/nyxoah-breathe-study-first-patient-implanted BiopharmaWatch en 2026-09-07T20:05:00.000Z Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System https://www.biopharmawatch.com/news/ASND/ascendis-endocrinology-rare-disease-data-espe-2026 BiopharmaWatch en 2026-09-07T11:00:00.000Z Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 https://www.biopharmawatch.com/news/NVO/novo-nordisk-step-young-phase-3-results BiopharmaWatch en 2026-09-07T10:00:00.000Z Novo Nordisk STEP Young phase 3 data: 40.4% of children living with obesity achieved a BMI below the obesity threshold with semaglutide and lifestyle modification https://www.biopharmawatch.com/blog/biotech-catalysts-to-watch-week-of-2026-09-07 BiopharmaWatch en 2026-09-07T07:15:28.530Z Biotech Catalysts to Watch: Key Developments for September 2026 https://www.biopharmawatch.com/news/ORBS/eightco-holdings-assets-openai-beast-industries BiopharmaWatch en 2026-09-07T05:15:00.000Z Eightco Holdings (NASDAQ: ORBS) gibt einen Gesamtbestand von rund 380 Millionen US-Dollar bekannt, darunter Anteile an OpenAI und Beast Industries sowie mehr als 16.000 ETH und fast 302 Millionen WLD-Token https://www.biopharmawatch.com/news/ORBS/eightco-holdings-assets-openai-beast-industries BiopharmaWatch en 2026-09-07T05:04:00.000Z Eightco Holdings (NASDAQ : ORBS) annonce un actif total d'environ 380 millions de dollars, comprenant notamment OpenAI, Beast Industries, plus de 16 000 jetons ETH et près de 302 millions de jetons WLD https://www.biopharmawatch.com/news/GENFF/genflow-biosciences-appoints-on365-investor-relations-adviser BiopharmaWatch en 2026-09-07T02:00:00.000Z Genflow Biosciences PLC Announces Appointment of Investor Relations Adviser